# Jasper Therapeutics (JSPR) — Analyst Forecast

JSPR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/jspr/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 4 | 0 | 0 | 4 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 14, 2026 | William Blair | Maintained | Outperform | — |
| Aug 12, 2026 | Piper Sandler | Initiated Coverage | Overweight | $2.00 |
| May 15, 2026 | RBC Capital | Maintained | Sector Perform | $3.00 |
| May 15, 2026 | TD Cowen | Downgraded | Buy → Hold | — |
| Apr 1, 2026 | Evercore ISI Group | Maintained | Outperform | $7.00 |
| Mar 23, 2026 | UBS | Initiated Coverage | Neutral | $1.50 |
| Nov 11, 2025 | RBC Capital | Maintained | Sector Perform | $4.00 |
| Sep 22, 2025 | BTIG | Maintained | Buy | $7.00 |
| Sep 22, 2025 | Evercore ISI Group | Maintained | Outperform | $14.00 |
| Sep 22, 2025 | JMP Securities | Maintained | Market Outperform | $6.00 |
| Aug 15, 2025 | UBS | Maintained | Buy | $25.00 |
| Jul 8, 2025 | Evercore ISI Group | Maintained | Outperform | $20.00 |
| Jul 8, 2025 | JMP Securities | Maintained | Market Outperform | $12.00 |
| Jul 8, 2025 | BMO Capital | Downgraded | Outperform → Market Perform | $4.00 |
| Jul 7, 2025 | BTIG | Maintained | Buy | $20.00 |
| Jul 7, 2025 | Cantor Fitzgerald | Downgraded | Overweight → Neutral | — |
| Jul 7, 2025 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Jul 7, 2025 | William Blair | Downgraded | Outperform → Market Perform | — |
| May 15, 2025 | Oppenheimer | Maintained | Outperform | $65.00 |
| May 13, 2025 | UBS | Maintained | Buy | $33.00 |

## Frequently Asked Questions

### Is JSPR a buy, sell, or hold?

Analysts covering Jasper Therapeutics currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on JSPR?

On Oct 14, 2026, William Blair maintained Jasper Therapeutics at Outperform.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).